{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=valsartan+%28ARB%29",
    "query": {
      "intervention": "valsartan (ARB)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=valsartan+%28ARB%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T14:33:54.998Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04206865",
      "title": "Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiogenic Shock"
      ],
      "interventions": [
        {
          "name": "Sacubitril-Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Standard Oral Vasodilators",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-11-25",
      "completion_date": "2020-09-10",
      "has_results": false,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04206865"
    },
    {
      "nct_id": "NCT01432106",
      "title": "The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Aliskerin/Valsartan and Rampiril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-02",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-18",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432106"
    },
    {
      "nct_id": "NCT04649229",
      "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "LCZ 696",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Para-aminohippurate",
          "type": "DRUG"
        },
        {
          "name": "Iohexol",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2021-05-27",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04649229"
    },
    {
      "nct_id": "NCT02226120",
      "title": "Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "LCZ696",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1980,
      "start_date": "2014-10-16",
      "completion_date": "2017-12-28",
      "has_results": true,
      "last_update_posted_date": "2019-02-20",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 24,
      "location_summary": "Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02226120"
    },
    {
      "nct_id": "NCT03738878",
      "title": "Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "LCZ696",
          "type": "DRUG"
        },
        {
          "name": "Bradykinin",
          "type": "DRUG"
        },
        {
          "name": "Substance P",
          "type": "DRUG"
        },
        {
          "name": "BNP",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-11-15",
      "completion_date": "2024-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03738878"
    },
    {
      "nct_id": "NCT02788656",
      "title": "Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Implantable Hemodynamic Monitor",
          "type": "DEVICE"
        },
        {
          "name": "Angiotensin-Converting Enzyme Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin II Type 1 Receptor Blocker",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-09",
      "completion_date": "2018-11-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788656"
    },
    {
      "nct_id": "NCT05168787",
      "title": "Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6558,
      "start_date": "2020-08-13",
      "completion_date": "2025-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05168787"
    },
    {
      "nct_id": "NCT06218199",
      "title": "Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure, Congestive"
      ],
      "interventions": [
        {
          "name": "Furosemide",
          "type": "DRUG"
        },
        {
          "name": "Torsemide",
          "type": "DRUG"
        },
        {
          "name": "Bumetanide",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "Hydralazine",
          "type": "DRUG"
        },
        {
          "name": "Isosorbide Dinitrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heart Center Research, LLC",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-07-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-01-29",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Huntsville, Alabama",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06218199"
    },
    {
      "nct_id": "NCT06029712",
      "title": "Heart Failure Polypill at a Safety Net Hospital",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Heart failure polypill",
          "type": "DRUG"
        },
        {
          "name": "Control Rx",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2024-02-27",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06029712"
    },
    {
      "nct_id": "NCT00657241",
      "title": "Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Carvedilol CR",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-04",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2022-05-27",
      "last_synced_at": "2026-09-25T14:33:54.998Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657241"
    }
  ]
}